CT-0508 + Pembrolizumab
Phase 1ActiveDevelopment Stage
HER2-positive
HER2-positive, Adenocarcinoma, Bile Duct Cancer, Biliary Tract Cancer, Bladder Cancer, Breast Cancer, Breast Neoplasm, Carcinoma, Ductal, Carcinoma, Hepatocellular, Cancer, Lung Cancer, Non-Small-Cell, Carcinoma, Ovarian Epithelial, Carcinoma, Small Cell, Carcinoma, Squamous, Carcinoma, Transitional Cell, Colorectal Cancer, Esophagogastric Junction Neoplasms, Inflammatory Breast Cancer, Stomach Neoplasms, Malignant Neoplasms, Ovarian Neoplasms, Pancreatic Cancer, HER2-positive Solid Tumors, HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER-2 Protein Overexpression, HER-2 Gene Amplification, Prostate Cancer, Head and Neck Cancer, Endometrial Cancer, Lung Cancer, Small Cell
Feb 2, 2021 โ Dec 31, 2024
About CT-0508 + Pembrolizumab
CT-0508 + Pembrolizumab is a phase 1 stage product being developed by Carisma Therapeutics for HER2-positive. The current trial status is active. This product is registered under clinical trial identifier NCT04660929. Target conditions include HER2-positive, Adenocarcinoma, Bile Duct Cancer.
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04660929 | Phase 1 | Active |
Competing Products
20 competing products in HER2-positive